

# Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



14<sup>th</sup> November, 2018

To,  
Corporate Relation Department  
**BSE Ltd**  
1<sup>st</sup> Floor, New Trade Wing,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.

**National Stock Exchange of India Limited**  
“Exchange Plaza”, 5<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051

**Scrip Code: 532637**

**Symbol: MANGALAM**

**Sub: Outcome of the Board Meeting held on 14<sup>th</sup> November, 2018**

Dear Sir,

In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that, the meeting of Board of Directors was held today i.e Wednesday, 14<sup>th</sup> November, 2018 at 11.30 A.M at the time scheduled for the meeting at the registered office of the company, where in the following business was inter-alia transacted:

1. Approved the Un-Audited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2018 along with the Limited Review Report on the results pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015;
2. Other Business transacted with permission of chair.


The Board Meeting concluded at 01.05 P.M.

You are requested to take the same on your records.

Thanking You,

Yours faithfully,  
For Mangalam Drugs & Organics Ltd

Nikita Bavishi  
Company Secretary



Works: at Vapi (Gujarat) India • E-Mail : [contactus@mangalamdrugs.com](mailto:contactus@mangalamdrugs.com) • Website : <http://www.mangalamdrugs.com>

**Un-Audited Financial Results for the Quarter & Half Year Ended 30th September 2018 approved and taken on record by the Board at their meeting dated 14th November,2018**

Sr.No	Particulars	Quarter Ended			Half Year Ended		Rs. In Lacs
		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A) Part-1 Statement of Un-Audited Financial Results for the Quarter and Half Year Ended September 30, 2018</b>							
1	Revenue from Operations	7,190.07	5,900.71	8,314.10	13,090.78	13,827.75	27,937.96
2	Other Income	3.84	2.77	3.69	6.61	8.10	82.70
3	Total Revenue(1+2)	7,193.91	5,903.48	8,317.79	13,097.39	13,835.85	28,020.66
4	Expenses						
	(a) Cost of Materials Consumed	5,471.41	3,710.56	4,441.25	9,181.97	8,412.81	18,047.91
	(b) Employee Benefits Expense	642.98	653.90	589.23	1,296.88	1,138.22	2,298.37
	(c) Changes in Inventories, Finished Goods and Stock-in-trade	(658.31)	85.11	680.49	(573.20)	(725.47)	(1,711.73)
	(d) Finance Costs	174.43	208.15	335.39	382.58	585.23	1,178.00
	(e) Depreciation	181.47	178.19	126.07	359.66	251.39	656.82
	(f) Other Expenses	1,179.20	984.85	1,115.29	2,144.05	2,527.81	4,616.57
	<b>Total Expenses</b>	<b>6,991.18</b>	<b>5,800.76</b>	<b>7,287.72</b>	<b>12,791.94</b>	<b>12,189.99</b>	<b>25,085.94</b>
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	202.73	102.72	1,030.07	305.45	1,645.86	2,934.72
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	202.73	102.72	1,030.07	305.45	1,645.86	2,934.72
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	202.73	102.72	1,030.07	305.45	1,645.86	2,934.72
10	Tax Expenses	29.93	35.89	360.19	65.82	560.38	945.76
11	Net Profit(+)/Loss(-) after Tax (9-10)	172.80	66.83	669.88	239.63	1,085.48	1,988.96
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	0.43	0.42	(4.94)	0.85	8.99	36.32
13	Total Comprehensive Income	173.23	67.25	664.94	240.48	1,094.47	2,025.28
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity						8,935.43
16	Earnings Per Share (EPS) (of Rs 10/-each)not annualised):						
	(a) Basic	1.09	0.42	4.23	1.51	6.86	12.57
	(b) Diluted	1.09	0.42	4.23	1.51	6.86	12.57

**Notes :**

- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on November 14, 2018. The Statutory Auditors have carried out a limited review of the results.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- W.e.f April 1, 2018, the Company has adopted Ind AS 115 – "Revenue from contracts with customers" under the full retrospective approach. Accordingly, the comparatives have been adjusted to give the effect of Ind AS 115. The effect on adoption of Ind AS 115 was insignificant on the financial results.
- Earlier period figures have been regrouped/ rearranged wherever necessary.

Place: Mumbai  
Date: 14th November, 2018

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M.Dhoot)  
Chairman & Managing Director  
(DIN:01240085)





Statement of Assets and Liabilities		
	₹ in Lacs	₹ in Lacs
	As at 30.09.2018 Unaudited	As at 31.03.2018 Audited
<b>ASSETS</b>		
<b>A. Non-current Assets</b>		
(a) Property, Plant and Equipment	10070.30	10115.60
(b) Capital Work-In-Progress	107.74	7.13
(c) Intangible assets	63.41	75.31
(c) Financial Assets		
(i) Loans	169.68	172.53
(ii) Other Financial Assets		
(iii) Deferred Tax Asset (Net)		
(d) Non Current Tax Assets (Net)		
(e) Other Non-current Assets		
<b>Total Non-current Assets (A)</b>	<b>10411.13</b>	<b>10,370.57</b>
<b>B. Current Assets</b>		
(a) Inventories	7530.63	6794.47
(b) Financial Assets		
(i) Investments	133.50	165.61
(ii) Trade Receivables	4643.53	4520.77
(iii) Cash and Cash Equivalents	96.95	43.03
(iv) Bank Balance other than Cash and Cash Equivalents		
(v) Loans	1485.10	1706.94
(vi) Others Financial Assets		
(c) Other Current Assets		
<b>Total Current Assets (B)</b>	<b>13889.71</b>	<b>13,230.82</b>
<b>TOTAL ASSETS</b>	<b>24300.84</b>	<b>23,601.39</b>
<b>EQUITY AND LIABILITIES</b>		
<b>A. Equity</b>		
(a) Equity Share Capital	1582.82	1582.82
(b) Other Equity	9175.90	8935.43
<b>Total Equity (A)</b>	<b>10758.72</b>	<b>10,518.25</b>
<b>B. Non-Current Liability</b>		
(a) Financial Liabilities		
(i) Borrowings	927.54	1114.64
(b) Deferred Tax Liabilities (Net)	1202.98	1202.98
(c) Provisions		
(d) Other Non-Current Liabilities		
<b>Total Non-current Liabilities (B)</b>	<b>2130.52</b>	<b>2,317.62</b>
<b>C. Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	4909.77	5075.19
(ii) Trade Payables	4069.74	3762.51
(iii) Other Financial Liabilities	534.60	703.08
(b) Other Current Liabilities	1480.05	1153.87
(c) Provisions	417.44	70.87
<b>Total Current Liabilities (C)</b>	<b>11411.60</b>	<b>10,765.51</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>24300.84</b>	<b>23,601.39</b>

Notes:- 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

Place: Mumbai  
Date: 14/11/2018



On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)  
Chairman & Managing Director  
(DIN:01240086)



**Independent Auditors' review report on the review of Interim Financial results  
for the Quarter and Half year ended September 2018.**

To,

**The Board of Directors of,  
Mangalam Drugs & Organics Limited.**

1. We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs & Organics Limited** ("the Company") for the quarter and six months ended 30<sup>th</sup> September, 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to the financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards as notified under the Companies ( Indian Accounting Standards) Rules, 2015 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai  
Date: November 14<sup>th</sup>, 2018



For Batliboi & Purohit  
Chartered Accountants  
FRN: 101048W

A handwritten signature in black ink, appearing to be "Raman Hangekar".

Raman Hangekar  
Partner  
M.No. 030615

**BRANCHES :**

NAVI MUMBAI : 302 / 304 Arenja Corner, Sector 17, Vashi, Navi Mumbai - 400 703. • Tel. : +91-22-2766 6478  
DELHI : 505, Nirmal Tower, 26, Barkhamba Road, New Delhi -110 001. • Tel. : +91-11-4019 0200